EU endorses dexamethasone for COVID-19 patients on oxygen therapy
(Reuters) - The European health regulator on Friday endorsed the use of widely known steroid dexamethasone in the treatment of COVID-19 patients on oxygen or mechanical ventilation.
The European Medicines Agency (EMA) said based on its review of results of a study by UK researchers, it concluded that dexamethasone - a commonly used drug against a range of inflammatory conditions - can be considered a treatment option in adults and adolescents needing oxygen therapy.
The recommended dose in adults and adolescents, from 12 years of age and weighing at least 40 kgs, is 6 milligrams once a day for up to 10 days, the EMA said. (https://bit.ly/3hFGHrK)
EMA recommends approval to the EU commission, which typically follows the recommendation for its approval decision.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.